市場調査レポート
商品コード
1069394

虚血性脳卒中市場 - 疫学に基づく現在の市場価値(2021年)と予測(2030年まで)、競合新薬の価格戦略、取引価値評価、r-NPV、パイプライン薬の分析(2022年上半期)

Ischemic Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report

出版日: | 発行: GervanoRA Data Services LLP | ページ情報: 英文 225 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
虚血性脳卒中市場 - 疫学に基づく現在の市場価値(2021年)と予測(2030年まで)、競合新薬の価格戦略、取引価値評価、r-NPV、パイプライン薬の分析(2022年上半期)
出版日: 2022年03月11日
発行: GervanoRA Data Services LLP
ページ情報: 英文 225 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要
当レポートでは、世界の虚血性脳卒中市場について調査し、市場の概要とともに、2030年までの予測、パイプライン動向、競合戦略などを提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 虚血性脳卒中の概要と疫学研究

第4章 虚血性脳卒中の現在の市場価値と予測:2021年~2030年

第5章 パイプラインの洞察とベンチマーキング概要

第6章 虚血性脳卒中の競合分野における取引活動

第7章 虚血性脳卒中パイプライン薬の比較特許分析

第8章 リスク調整正味現在価値(R-NPV)分析

第9章 競合機会の評価

第10章 市場力学

第11章 競合企業の新薬の価格戦略

図表

LIST OF TABLES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: WORLDWIDE EPIDEMIOLOGY INSIGHTS OF ISCHEMIC STROKE
  • TABLE 03: GLOBAL ISCHEMIC STROKE EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 04: US ISCHEMIC STROKE EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 05: UK ISCHEMIC STROKE EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 06: LIST OF NEW ENTRANTS CONSIDERED FOR MARKET ESTIMATIONS
  • TABLE 07: ISCHEMIC STROKE GLOBAL CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 08: ISCHEMIC STROKE US CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 09: COMPARISON OF ISCHEMIC STROKE MARKET VALUES GLOBAL VERSUS US (2020-2030)(M$)
  • TABLE 10: PIPELINE ASSETS IN ISCHEMIC STROKE DRUG PIPELINE
  • TABLE 11: SPECIAL REGULATORY ALLOWANCES GRANTED FOR ISCHEMIC STROKE PIPELINE DRUGS
  • TABLE 12: ISCHEMIC STROKE PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
  • TABLE 13: ISCHEMIC STROKE PIPELINE ANALYTICS BY DRUG CLASS
  • TABLE 14: ISCHEMIC STROKE PIPELINE ANALYTICS BY MECHANISM OF ACTION
  • TABLE 15: ISCHEMIC STROKE PIPELINE ANALYTICS BY MOLECULE TYPE
  • TABLE 16: MAJOR MERGERS AND ACQUISITIONS IN ISCHEMIC STROKE THERAPEUTIC AREA
  • TABLE 17: MAJOR COLLABORATION AGREEMENTS IN ISCHEMIC STROKE THERAPEUTIC AREA
  • TABLE 18: MAJOR LICENSING AGREEMENTS IN ISCHEMIC STROKE THERAPEUTIC AREA
  • TABLE 19: MAJOR FINANCING AGREEMENTS IN ISCHEMIC STROKE THERAPEUTIC AREA
  • TABLE 20: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN ISCHEMIC STROKE THERAPEUTIC AREA
  • TABLE 21: COMPANIES LOOKING FOR CORPORATE PARTNERING, LICENSING, FUNDING OPPORTUNITIES
  • TABLE 22: ESTIMATED R&D INVESTMENTS OF NEW ENTRANTS

LIST OF FIGURES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: ISCHEMIC STROKE FORECASTED PREVALENCE & INCIDENCE OF US, EUROPE AND CHINA, 2020 V/S 2030
  • FIGURE 02: GLOBAL ISCHEMIC STROKE POPULATION (2020) FORECAST (2021-2030)
  • FIGURE 03: US ISCHEMIC STROKE POPULATION (2020) FORECAST (2021-2030)
  • FIGURE 04: GLOBAL ISCHEMIC STROKE MARKET CURRENT (2020) AND FORECAST (2021-2030)
  • FIGURE 05: US CURRENT (2020) ISCHEMIC STROKE MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 06: YEAR BY YEAR COMPARISON OF ISCHEMIC STROKE MARKET VALUES GLOBAL VS USA (2020 - 2030) (M$)
  • FIGURE 07: ISCHEMIC STROKE PIPELINE DRUGS ANALYTICS
  • FIGURE 08: ISCHEMIC STROKE PIPELINE DRUGS ANALYTICS BY HSD
  • FIGURE 09: ISCHEMIC STROKE PIPELINE ANALYTICS BY ROA
  • FIGURE 10: ISCHEMIC STROKE PIPELINE ANALYTICS BY DRUG CLASS
  • FIGURE 11: ISCHEMIC STROKE PIPELINE ANALYTICS BY DRUG CLASS VERSUS HSD
  • FIGURE 12: ISCHEMIC STROKE PIPELINE ANALYTICS BY MECHANISM OF ACTION
  • FIGURE 13: ISCHEMIC STROKE PIPELINE ANALYTICS BY MOLECULE TYPE
  • FIGURE 14: ISCHEMIC STROKE PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 15: ISCHEMIC STROKE DEALS ANALYTICS BY DEAL TYPE
目次
Product Code: GERPH535

GervanoRA's pipeline analysis and opportunity assessment report, "Ischemic Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022" analysed and assessed Ischemic Stroke pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Ischemic Stroke drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Ischemic Stroke area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Ischemic Stroke drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Ischemic Stroke historical and forecasted epidemiology based market trends Worldwide, the United States, EU8 (Poland, Spain, Switzerland, Sweden, Italy, Germany, Austria, France), United Kingdom and China. A detailed analytics on the Current Ischemic Stroke Market (2021) and the Forecasted Ischemic Stroke Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Ischemic Stroke Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Ischemic Stroke Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Ischemic Stroke Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: ISCHEMIC STROKE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: ISCHEMIC STROKE CURRENT MARKET VALUE AND FORECAST 2021 - 2030

CHAPTER 5: COMPARATIVE PIPELINE INSIGHTS AND BENCHMARKING SNAPSHOTS

CHAPTER 6: DEALS ACTIVITIES OF ISCHEMIC STROKE COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF ISCHEMIC STROKE PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

CHAPTER 10: MARKET DYNAMICS

CHAPTER 11: COMPETITOR NEW DRUGS PRICING STRATEGIES